Company news

Editas Medicine, Inc. news in 2024

Editas Medicine, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

December 11, 2024

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

December 8, 2024

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

November 3, 2024

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

October 21, 2024

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

October 20, 2024

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

October 17, 2024

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

October 2, 2024

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

August 6, 2024

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

July 30, 2024

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

June 13, 2024

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

June 13, 2024

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

May 13, 2024

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

May 9, 2024

Editas Medicine Announces First Quarter 2024 Results and Business Updates

May 7, 2024

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

May 1, 2024

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

April 30, 2024

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

April 21, 2024

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

February 27, 2024

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

February 20, 2024

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

January 7, 2024

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024